- Home
- PGEN vs TERN Comparison
PGEN vs TERN Comparison
Compare PGEN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGEN
- TERN
- Stock Information
- Founded
- PGEN 1998
- TERN 2017
- Country
- PGEN United States
- TERN United States
- Employees
- PGEN N/A
- TERN N/A
- Industry
- PGEN Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PGEN Health Care
- TERN Health Care
- Exchange
- PGEN Nasdaq
- TERN Nasdaq
- Market Cap
- PGEN 448.7M
- TERN 531.9M
- IPO Year
- PGEN N/A
- TERN 2021
- Fundamental
- Price
- PGEN $1.67
- TERN $5.47
- Analyst Decision
- PGEN Strong Buy
- TERN Buy
- Analyst Count
- PGEN 3
- TERN 5
- Target Price
- PGEN $6.00
- TERN $15.63
- AVG Volume (30 Days)
- PGEN 3.0M
- TERN 1.0M
- Earning Date
- PGEN 08-13-2025
- TERN 08-12-2025
- Dividend Yield
- PGEN N/A
- TERN N/A
- EPS Growth
- PGEN N/A
- TERN N/A
- EPS
- PGEN N/A
- TERN N/A
- Revenue
- PGEN $4,201,000.00
- TERN N/A
- Revenue This Year
- PGEN $256.94
- TERN N/A
- Revenue Next Year
- PGEN $759.81
- TERN N/A
- P/E Ratio
- PGEN N/A
- TERN N/A
- Revenue Growth
- PGEN N/A
- TERN N/A
- 52 Week Low
- PGEN $0.65
- TERN $1.87
- 52 Week High
- PGEN $2.17
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PGEN 51.21
- TERN 56.99
- Support Level
- PGEN $1.54
- TERN $5.57
- Resistance Level
- PGEN $1.85
- TERN $6.10
- Average True Range (ATR)
- PGEN 0.14
- TERN 0.28
- MACD
- PGEN -0.02
- TERN -0.06
- Stochastic Oscillator
- PGEN 40.00
- TERN 41.04
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.